Safety and efficacy of ranirestat in patients with mild‐to‐moderate diabetic sensorimotor polyneuropathy

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Journal of the peripheral nervous system

• Publication date

  2015-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/jns.12138PMID 26313450
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Effects of Long-Term Treatment with Ranirestat, a Potent Aldose Reductase Inhibitor, on Diabetic Cataract and Neuropathy in Spontaneously Diabetic Torii Rats

  2013influential reference
• The evolving natural history of neurophysiologic function in patients with well‐controlled diabetes

  2013influential reference
• Interplay of sorbitol pathway of glucose metabolism, 12/15-lipoxygenase, and mitogen-activated protein kinases in the pathogenesis of diabetic peripheral neuropathy.

  2012cited by this paper
• Efficacy and Safety of Antioxidant Treatment With α-Lipoic Acid Over 4 Years in Diabetic Polyneuropathy

  2011influential reference
• Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics.

  2009cited by this paper
• Ranirestat for the Management of Diabetic Sensorimotor Polyneuropathy

  2009influential reference
• Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study

  2008cited by this paper
• Aldose reductase, still a compelling target for diabetic neuropathy.

  2008cited by this paper
• Diabetic neuropathy in older adults.

  2008cited by this paper
• Long-term effects of ranirestat (AS-3201) on peripheral nerve function in patients with diabetic sensorimotor polyneuropathy.

  2006influential reference
• Distal symmetric polyneuropathy: A definition for clinical research

  2005cited by this paper
• Development and validity testing of the neuropathy total symptom score-6: questionnaire for the study of sensory symptoms of diabetic peripheral neuropathy.

  2005cited by this paper
• Diabetic Neuropathy in Older Adults

  2005cited by this paper
• The time course of epidermal nerve fibre regeneration: studies in normal controls and in people with diabetes, with and without neuropathy.

  2004cited by this paper
• Aldose reductase inhibition by AS-3201 in sural nerve from patients with diabetic sensorimotor polyneuropathy.

  2004cited by this paper
• Can motor nerve conduction velocity predict foot problems in diabetic subjects over a 6-year outcome period?

  2002cited by this paper
• Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial.

  1998cited by this paper
• Longitudinal assessment of diabetic polyneuropathy using a composite score in the Rochester Diabetic Neuropathy Study cohort

  1997influential reference
• Effect of intensive diabetes treatment on nerve conduction in the diabetes control and complications trial

  1995cited by this paper
• Natural history of peripheral neuropathy in patients with non-insulin-dependent diabetes mellitus.

  1995influential reference
• Complications: Neuropathy, Pathogenetic Considerations

  1992cited by this paper
• Meaningful Degrees of Prevention or Improvement of Nerve Conduction in Controlled Clinical Trials of Diabetic Neuropathy

  1989cited by this paper
• New tables for multiple comparisons with a control.

  1964cited by this paper
• A Multiple Comparison Procedure for Comparing Several Treatments with a Control

  1955cited by this paper

• Immunological mechanisms and therapeutic advances in diabetic neuropathy

  2026cites this paper
• AKR1B1 bridges metabolic pathways and disease progression.

  2025cites this paper
• An Investigation of 5-Halogenated N-Indolylsulfonyl-2-fluorophenol Derivatives as Aldose Reductase Inhibitors

  2025cites this paper
• Aldo-Keto Reductase 1B: much learned, much more to do

  2023cites this paper
• Current and Emerging Pharmacotherapeutic Interventions for the Treatment of Peripheral Nerve Disorders

  2022cites this paper
• Ranirestat Improves Electrophysiologic but not Clinical Measures of Diabetic Polyneuropathy: A Meta-Analysis

  2022influential citation
• Diagnostic tools, biomarkers, and treatments in diabetic polyneuropathy and cardiovascular autonomic neuropathy.

  2021cites this paper
• The time to develop treatments for diabetic neuropathy

  2021cites this paper
• Biallelic mutations in SORD cause a common and potentially treatable hereditary neuropathy with implications for diabetes

  2020cites this paper
• Pharmacokinetics and Safety of Ranirestat in Patients With Hepatic Impairment

  2020cites this paper
• Current concepts in the management of diabetic polyneuropathy

  2020cites this paper
• Development of aldose reductase inhibitors for the treatment of inflammatory disorders and cancer: current drug design strategies and future directions.

  2020cites this paper
• Lost in Translation? Measuring Diabetic Neuropathy in Humans and Animals

  2020cites this paper
• Diabetic neuropathy

  2019cites this paper
• Aldose reductase inhibitor ranirestat significantly improves nerve conduction velocity in diabetic polyneuropathy: A randomized double‐blind placebo‐controlled study in Japan

  2018cites this paper
• Sensory and autonomic function and structure in footpads of a diabetic mouse model

  2017cites this paper
• Diabetic Neuropathy: Current Status and Future Prospects

  2017cites this paper
• Schwann cell interactions with axons and microvessels in diabetic neuropathy

  2017cites this paper
• Laser Doppler Imager Flare (LDIflare) small fibre function

  2017cites this paper
• Effect of Ranirestat on Sensory and Motor Nerve Function in Japanese Patients with Diabetic Polyneuropathy: A Randomized Double-Blind Placebo-Controlled Study

  2016cites this paper
• Glucotoxic Mechanisms and Related Therapeutic Approaches.

  2016cites this paper
• Higher body fat percentage is associated with enhanced temperature 1 perception in NAFLD: results from the randomised WELCOME* trial

  2016cites this paper
• Higher body fat percentage is associated with enhanced temperature perception in NAFLD: results from the randomised Wessex Evaluation of fatty Liver and Cardiovascular markers in NAFLD with OMacor thErapy trial (WELCOME) trial

  2016cites this paper
• Aldose reductase, ocular diabetic complications and the development of topical Kinostat(®).

  2016cites this paper
• Diabetic Polyneuropathy in Type 2 Diabetes Mellitus: Inflammation, Oxidative Stress, and Mitochondrial Function

  2016cites this paper
• Emerging drugs for diabetic peripheral neuropathy and neuropathic pain

  2016cites this paper
• A Brief Introduction to the History and Controversies of Clinical Trials in Diabetic Neuropathy.

  2016cites this paper